Clinical implications of the progression-free survival endpoint for treatment of hormone receptor-positive advanced breast cancer

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Hormonal therapy for advanced breast cancer (ABC) has evolved significantly since the introduction of tamoxifen more than 40 years ago. The availability of selective antiestrogen therapies has further improved treatment options for women with hormone receptor-positive (HR1) ABC. However, with the development of resistance to hormonal therapies, a new treatment paradigm has emerged based on our understanding of biological pathways involved in HR1 breast cancer and mechanisms of resistance to hormonal therapy. Recent drug development efforts have focused on combining hormonal treatment with agents that target mammalian target of rapamycin serine-threonine kinases and cyclin-dependent kinases. In parallel with the evolution of hormonal and targeted therapies, our understanding of the utility of clinical endpoints has deepened. Progression-free survival (PFS) is a primary endpoint well-understood by clinicians and is increasingly accepted as a surrogate for overall survival (OS) by the U.S. Food and Drug Administration. Yet the perceived clinical benefit of PFS to patients is less well understood. Patients may not grasp the implications of prolonged PFS, highlighting the reality that patient preference in treatment selection encompasses factors that extend beyond drug activity. This presents an opportunity for clinicians to discuss PFS with patients in the context of their treatment plans, clinical outcomes, and quality-of-life measures. The objective of this review is to explore the clinical validity of the PFS andOS endpoints and the clinical relevance of PFS and OS to patients, especially in light of drivers that led to a range of treatment options for patients with HR1 ABC.

Original languageEnglish (US)
Pages (from-to)922-930
Number of pages9
JournalOncologist
Volume21
Issue number8
DOIs
StatePublished - Aug 2016

Keywords

  • Breast cancer
  • Cyclin-dependent kinases
  • Progression-free survival
  • mTOR serine-threonine kinases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical implications of the progression-free survival endpoint for treatment of hormone receptor-positive advanced breast cancer'. Together they form a unique fingerprint.

Cite this